SI2275103T1 - mTor inhibitorji pri zdravljenju endokrinih tumorjev - Google Patents
mTor inhibitorji pri zdravljenju endokrinih tumorjevInfo
- Publication number
- SI2275103T1 SI2275103T1 SI200631791T SI200631791T SI2275103T1 SI 2275103 T1 SI2275103 T1 SI 2275103T1 SI 200631791 T SI200631791 T SI 200631791T SI 200631791 T SI200631791 T SI 200631791T SI 2275103 T1 SI2275103 T1 SI 2275103T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treatment
- mtor inhibitors
- endocrine tumors
- endocrine
- tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0523658A GB0523658D0 (en) | 2005-11-21 | 2005-11-21 | Organic compounds |
GB0601082A GB0601082D0 (en) | 2006-01-19 | 2006-01-19 | Organic Compounds |
GB0602747A GB0602747D0 (en) | 2006-02-10 | 2006-02-10 | Organic compounds |
GB0607942A GB0607942D0 (en) | 2006-04-21 | 2006-04-21 | Organic compounds |
GB0609272A GB0609272D0 (en) | 2006-05-10 | 2006-05-10 | Organic compounds |
GB0609912A GB0609912D0 (en) | 2006-05-18 | 2006-05-18 | Organic compounds |
EP06120660 | 2006-09-14 | ||
EP10175197.2A EP2275103B1 (en) | 2005-11-21 | 2006-11-20 | mTOR inhibitors in the treatment of endocrine tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2275103T1 true SI2275103T1 (sl) | 2014-07-31 |
Family
ID=37671355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200631791T SI2275103T1 (sl) | 2005-11-21 | 2006-11-20 | mTor inhibitorji pri zdravljenju endokrinih tumorjev |
Country Status (22)
Country | Link |
---|---|
US (3) | US9006224B2 (sl) |
EP (3) | EP2275103B1 (sl) |
JP (3) | JP2009516671A (sl) |
KR (2) | KR20140012218A (sl) |
CN (1) | CN103446138A (sl) |
AU (2) | AU2006314444C1 (sl) |
BR (1) | BRPI0618808A2 (sl) |
CA (2) | CA2933875C (sl) |
CY (1) | CY1115299T1 (sl) |
DK (1) | DK2275103T3 (sl) |
ES (1) | ES2481671T3 (sl) |
HK (1) | HK1150746A1 (sl) |
HR (1) | HRP20140708T1 (sl) |
IL (3) | IL191475A (sl) |
MA (1) | MA29966B1 (sl) |
NO (4) | NO346575B1 (sl) |
NZ (1) | NZ568182A (sl) |
PL (1) | PL2275103T3 (sl) |
PT (1) | PT2275103E (sl) |
RU (1) | RU2487711C2 (sl) |
SI (1) | SI2275103T1 (sl) |
WO (1) | WO2007057457A2 (sl) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ527692A (en) | 2001-02-19 | 2005-05-27 | Novartis Ag | Cancer treatment |
WO2007115289A2 (en) * | 2006-04-05 | 2007-10-11 | Novartis Ag | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
EP2004163B1 (en) | 2006-04-05 | 2014-09-17 | Novartis Pharma AG | Combination of everolimus and vinorelbine |
AU2013205002B2 (en) * | 2008-03-21 | 2016-09-15 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
KR101683314B1 (ko) | 2008-09-17 | 2016-12-06 | 키아스마 인코포레이티드 | 약제학적 조성물 및 연관된 투여방법 |
WO2010151517A2 (en) | 2009-06-25 | 2010-12-29 | The Regents Of The University Of Michigan | Antigen-specific long-term memory t-cells |
US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
PL2545045T3 (pl) | 2010-03-10 | 2016-08-31 | Incyte Holdings Corp | Pochodne piperydyn-4-yloazetydyny jako inhibitory JAK1 |
ES2894958T3 (es) * | 2011-10-19 | 2022-02-16 | Signal Pharm Llc | Tratamiento del cáncer con inhibidores de la quinasa TOR |
AU2014223501A1 (en) * | 2013-02-28 | 2015-09-17 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
EP2967059A4 (en) * | 2013-03-15 | 2017-03-22 | The Board of Regents of The University of Texas System | Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth |
WO2014193912A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
MA41462A (fr) | 2015-02-03 | 2021-05-12 | Chiasma Inc | Méthode de traitement de maladies |
WO2017000085A1 (zh) * | 2015-06-30 | 2017-01-05 | 上海交通大学 | Sunlidac在制备抗肺癌产品中的应用 |
AU2017210227A1 (en) * | 2016-01-21 | 2018-09-06 | Amryt Endo, Inc. | Oral octreotide for the treatment of disease |
WO2018204477A1 (en) * | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
TWI787284B (zh) | 2017-06-22 | 2022-12-21 | 美商西建公司 | 以b型肝炎病毒感染表徵之肝細胞癌之治療 |
WO2019157363A2 (en) * | 2018-02-09 | 2019-08-15 | Mount Tam Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of cancer |
KR20210018243A (ko) | 2018-05-01 | 2021-02-17 | 레볼루션 메디슨즈, 인크. | mTOR 억제제로서의 C26-연결된 라파마이신 유사체 |
WO2020191002A1 (en) * | 2019-03-18 | 2020-09-24 | The Regents Of The University Of California | Compositions and methods for treating cushing's disease |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
CN117412772A (zh) * | 2021-06-07 | 2024-01-16 | 纳米药业有限责任公司 | 用于双靶向治疗神经内分泌瘤的组合物和方法 |
US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
GB9013448D0 (en) * | 1990-06-15 | 1990-08-08 | Sandoz Ltd | Pharmaceutical resorption-improved somatostatin compositions,their preparation and use |
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
TW225528B (sl) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5234140A (en) | 1992-07-28 | 1993-08-10 | S. C. Johnson & Son, Inc. | Re-useable aerosol container |
SK285035B6 (sk) | 1992-10-28 | 2006-05-04 | Genentech, Inc. | Antagonisty rastového faktora vaskulárnych endotelových buniek |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
MY129435A (en) | 1994-10-26 | 2007-04-30 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
CA2224435C (en) | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
IT1277391B1 (it) * | 1995-07-28 | 1997-11-10 | Romano Deghenghi | Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
CA2249446C (en) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
US6362164B1 (en) * | 1996-06-11 | 2002-03-26 | Novartis Ag | Combination of a somatostatin analogue and a rapamycin |
DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
US5932613A (en) | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
AU4342997A (en) | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
WO1998022461A1 (de) | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
IL138113A0 (en) | 1998-02-25 | 2001-10-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto and analogues thereof |
PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
CA2350189A1 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
EP1140173B2 (en) | 1998-12-22 | 2013-04-03 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
PT1165085E (pt) | 1999-03-30 | 2006-10-31 | Novartis Ag | Derivados de ftalazina para tratar doencas inflamatorias |
WO2001014387A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
RU2264405C2 (ru) | 1999-12-06 | 2005-11-20 | Новартис Аг | 40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
NZ525656A (en) | 2000-11-07 | 2004-12-24 | Novartis Ag | Indolylmaleimide derivatives as protein kinase C inhibitors |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
NZ527692A (en) * | 2001-02-19 | 2005-05-27 | Novartis Ag | Cancer treatment |
CN1309421C (zh) * | 2001-04-06 | 2007-04-11 | 惠氏公司 | 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合 |
TWI296196B (en) | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
US20030008923A1 (en) | 2001-06-01 | 2003-01-09 | Wyeth | Antineoplastic combinations |
EP1392286A2 (en) * | 2001-06-01 | 2004-03-03 | Wyeth | Antineoplastic combinations |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
CN100522967C (zh) | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | 含磷化合物及其应用 |
TWI324064B (en) | 2002-04-03 | 2010-05-01 | Novartis Ag | Indolylmaleimide derivatives |
AU2003248813A1 (en) * | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
KR20050084224A (ko) | 2002-12-09 | 2005-08-26 | 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 야누스 티로신 키나제 3을 선택적으로 저해하는 방법 |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
US7160867B2 (en) | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
WO2005064343A1 (en) | 2003-12-22 | 2005-07-14 | Novartis Ag | Biomarkers for sensitivity of proliferative diseases to mtor inhibitors |
EP1704145B1 (en) | 2004-01-12 | 2012-06-13 | YM BioSciences Australia Pty Ltd | Selective kinase inhibitors |
BRPI0507834A (pt) * | 2004-02-23 | 2007-07-10 | Sugen Inc | método para tratar o crescimento celular anormal usando inibidores de c-met e de m-tor |
JP5005355B2 (ja) * | 2004-02-23 | 2012-08-22 | ノバルティス アーゲー | 細胞毒性因子と組み合わせたmTOR阻害剤での処置のためのバイオマーカーとしてのp53野生型 |
MX2007007212A (es) | 2004-12-15 | 2007-11-07 | Novartis Ag | Combinaciones de agentes terapeuticos para el tratamiento del cancer. |
US20060160837A1 (en) | 2004-12-29 | 2006-07-20 | The Brigham And Women's Hospital, Inc. | Rapamycin compounds in the treatment of neurofibromatosis type 1 |
-
2006
- 2006-11-20 ES ES10175197.2T patent/ES2481671T3/es active Active
- 2006-11-20 CA CA2933875A patent/CA2933875C/en active Active
- 2006-11-20 NO NO20170956A patent/NO346575B1/no unknown
- 2006-11-20 PL PL10175197T patent/PL2275103T3/pl unknown
- 2006-11-20 EP EP10175197.2A patent/EP2275103B1/en not_active Revoked
- 2006-11-20 NO NO20220050A patent/NO20220050A1/no not_active Application Discontinuation
- 2006-11-20 AU AU2006314444A patent/AU2006314444C1/en active Active
- 2006-11-20 BR BRPI0618808-7A patent/BRPI0618808A2/pt not_active Application Discontinuation
- 2006-11-20 CN CN2013103848215A patent/CN103446138A/zh active Pending
- 2006-11-20 DK DK10175197.2T patent/DK2275103T3/da active
- 2006-11-20 RU RU2008124827/15A patent/RU2487711C2/ru active
- 2006-11-20 EP EP08162295A patent/EP2022498A3/en not_active Withdrawn
- 2006-11-20 NZ NZ568182A patent/NZ568182A/en unknown
- 2006-11-20 KR KR1020147001555A patent/KR20140012218A/ko not_active Application Discontinuation
- 2006-11-20 JP JP2008540626A patent/JP2009516671A/ja not_active Withdrawn
- 2006-11-20 WO PCT/EP2006/068656 patent/WO2007057457A2/en active Application Filing
- 2006-11-20 EP EP06819607A patent/EP1954269A2/en not_active Withdrawn
- 2006-11-20 CA CA2629245A patent/CA2629245C/en active Active
- 2006-11-20 PT PT101751972T patent/PT2275103E/pt unknown
- 2006-11-20 SI SI200631791T patent/SI2275103T1/sl unknown
- 2006-11-20 US US12/094,173 patent/US9006224B2/en active Active
- 2006-11-20 KR KR1020087014937A patent/KR20080071600A/ko not_active Application Discontinuation
-
2008
- 2008-05-15 IL IL191475A patent/IL191475A/en active IP Right Grant
- 2008-05-20 MA MA30950A patent/MA29966B1/fr unknown
- 2008-06-16 NO NO20082683A patent/NO344288B1/no unknown
- 2008-09-23 HK HK11104451.1A patent/HK1150746A1/xx unknown
-
2010
- 2010-07-07 AU AU2010202866A patent/AU2010202866A1/en not_active Abandoned
-
2013
- 2013-04-03 JP JP2013077748A patent/JP5833048B2/ja active Active
-
2014
- 2014-06-20 CY CY20141100454T patent/CY1115299T1/el unknown
- 2014-07-22 HR HRP20140708TT patent/HRP20140708T1/hr unknown
- 2014-12-03 JP JP2014245402A patent/JP5963836B2/ja active Active
-
2015
- 2015-01-29 US US14/608,644 patent/US20150148294A1/en not_active Abandoned
-
2016
- 2016-06-22 NO NO20161045A patent/NO341023B1/no unknown
-
2017
- 2017-01-13 US US15/405,501 patent/US20170128425A1/en not_active Abandoned
- 2017-02-21 IL IL250697A patent/IL250697A0/en unknown
- 2017-07-27 IL IL253698A patent/IL253698A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2275103E (pt) | Inibidores de mtor para o tratamento de tumores endócrinos | |
IL188430A0 (en) | Treatment of tumors | |
PL2100618T3 (pl) | Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości | |
IL186447A0 (en) | Methods for the treatment of substance abuse and dependence | |
PL2101731T3 (pl) | Endoksyfen do zastosowania w leczeniu nowotworu | |
IL186408A0 (en) | Combination treatment methods | |
IL176919A0 (en) | Methods and compositions for treating cancer | |
EP1845970A4 (en) | INHIBITORS OF TUMOR NECROSIS FACTOR | |
HK1215683A1 (zh) | 抗葉酸藥在癌症治療中的聯合應用 | |
PT1611890E (pt) | Métodos para avaliação e tratamento do cancro | |
IL185258A (en) | Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human | |
PT1830847E (pt) | Tratamento para o cancro | |
HK1117780A1 (en) | Compounds and methods for the treatment of cancer | |
EP1855662A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
AU2006251167A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
AU2006251169A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
GB0517387D0 (en) | Combinations for the treatment of cancer | |
ZA200709443B (en) | Methods for the treatment of substance abuse and dependence | |
EP1904088A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
IL226363A0 (en) | Compounds and methods for treating cancer | |
ZA200804027B (en) | Neuroendocrine tumor treatment using m TOR inhibitors | |
GB0516610D0 (en) | Compounds for use in therapy | |
GB0517386D0 (en) | Combinations for the treatment of cancer | |
GB0522671D0 (en) | Spisulosine compounds for use in cancer therapy |